SCNIScinai Immunotherapeutics Ltd.

Nasdaq biondvax.com


$ 0.45 $ -0.01 (-3.19 %)    

Monday, 13-May-2024 11:08:32 EDT
QQQ $ 443.94 $ -0.84 (-0.19 %)
DIA $ 394.34 $ -0.75 (-0.19 %)
SPY $ 521.24 $ -0.95 (-0.18 %)
TLT $ 90.50 $ -0.11 (-0.12 %)
GLD $ 217.30 $ -0.54 (-0.25 %)
$ 0.455
$ 0.45
$ 0.00 x 0
$ 0.00 x 0
$ 0.45 - $ 0.45
$ 0.43 - $ 2.27
12,312
na
14.94M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2023 03-31-2023 10-Q
2 04-17-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 scinai-immunotherapeutics-cdmo-unit-and-ayana-pharma-signed-a-five-year-master-service-agreement-to-provide-drug-development-and-cgmp-manufacturing-services

Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assu...

 scinai-reports-preclinical-trial-results-of-its-antiil17-vhh-antibody-intends-to-conduct-an-in-vivo-proof-of-concept-animal-study-in-early-2024

The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psor...

 scinai-immunotherapeutics-ltd-announces-the-publication-following-peer-review-of-an-article-titled-nanobodies-to-multiple-spike-variants-and-inhalation-of-nanobody-containing-aerosols-neutralize-sars-cov-2-in-cell-culture-and-hamsters

Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, address...

 scinai-immunotherapeutics-provides-update-regarding-nasdaq-compliance

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company focused on developing, manufacturing, and commerciali...

 european-investment-bank-considering-extending-maturity-of-its-financial-facility-contract-with-scinai-immunotherapeutics-in-light-of-scinais-recent-strategic-pivot

Recently rebranded Scinai Immunotherapeutics shifted drug development focus from COVID-19 antibody to a novel antibody for the ...

 scinai-immunotherapeutics-q3-eps-002-down-from-006-yoy

Scinai Immunotherapeutics (NASDAQ:SCNI) reported quarterly losses of $(0.02) per share. This is a 133.33 percent decrease over ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION